Reports Q2 revenue $7.84M, consensus $8.21M. Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera Inc., stated, “This was a very exciting period for us as we got our sales and marketing efforts in full swing during the first half of the year. Additionally, on June 10th we launched the commercial distribution of the RhodoLED XL and I am pleased to say that we shipped the first three machines within 1 week of launch. The RhodoLED XL is approved by the FDA in combination with Ameluz(R).”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BFRI:
- Biofrontera, Inc. (BFRI) Q2 Earnings Cheat Sheet
- Biofrontera Unveils RhodoLED® XL Lamp, Eyes Market Growth
- Biofrontera Inc. announces launch of RhodoLED XL lamp
- Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
- Biofrontera Stockholders Approve Key Governance Decisions